OncoMatch/Clinical Trials/NCT04892953
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Is NCT04892953 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for stage iii lung cancer ajcc v8.
Treatment: Carboplatin · Durvalumab · Gemcitabine · Nab-paclitaxel · Paclitaxel · Pemetrexed — This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab may help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIA, IIIB, IIIC, III (AJCC 7th and 8th edition)
Stage III NSCLC (AJCC 7th and 8th edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemoradiation — definitive
patients who received standard chemoradiation followed by durvalumab therapy
Must have received: anti-PD-L1 therapy (durvalumab) — post-chemoradiation
patients who received standard chemoradiation followed by durvalumab therapy
Cannot have received: anti-PD-(L)1 therapy other than durvalumab
Patients who were treated with anti-PD-(L)1 therapy other than durvalumab
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; Platelet count ≥ 75 × 10^9/L
Kidney function
Measured creatinine clearance (CL) > 15 mL/min or calculated creatinine CL > 15 mL/min
Liver function
Serum bilirubin ≤ 1.5 x institutional ULN (except Gilbert's syndrome); AST/ALT ≤ 2.5 x ULN unless liver metastases present, then ≤ 5 x ULN
Cardiac function
Mean QTcF < 470 ms (from 3 ECGs within 15 minutes at 5 minutes apart)
Hemoglobin ≥ 9.0 g/dL; Platelet count ≥ 75 × 10^9/L; Serum bilirubin ≤ 1.5 x institutional ULN ... AST/ALT ≤ 2.5 x ULN unless liver metastases ... Measured creatinine clearance (CL) > 15 mL/min ... Mean QTcF < 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify